menu search

VYYRF / Voyageur Pharmaceuticals completes production testing of SmoothX; begins scale-up for Canadian imaging market

Voyageur Pharmaceuticals completes production testing of SmoothX; begins scale-up for Canadian imaging market
Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) said it has completed the production test batch of its SmoothX barium contrast suspension for the computed tomography (CT) imaging market in Canada. The company said this is a significant development as it transitions from the development phase to the production phase, where the focus will now be on scaling up the commercial volumes of SmoothX to supply the Canadian imaging market. Read More
Posted: Nov 28 2022, 09:11
Author Name: Proactive Investors
Views: 111459

VYYRF News  

Voyageur Pharmaceuticals achieves milestone in the development of HDXBa barium contrast media

By Proactive Investors
September 14, 2023

Voyageur Pharmaceuticals achieves milestone in the development of HDXBa barium contrast media

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) told investors it has completed the formulation and engineering for production processing of its dr more_horizontal

Voyageur Pharmaceuticals appoints seasoned executive to board; files interim financial statements

By Proactive Investors
August 1, 2023

Voyageur Pharmaceuticals appoints seasoned executive to board; files interim financial statements

Voyageur Pharmaceuticals said it is adding experienced finance and accounting professional Kevin R. McBeth to its board following the retirement of more_horizontal

Large-scale fullerene production opens up world of possibilities in medicine, electronics

By Proactive Investors
June 16, 2023

Large-scale fullerene production opens up world of possibilities in medicine, electronics

A Calgary-based company has unveiled a new process to produce fullerenes and their derivatives, which are among the world's most valuable materials, o more_horizontal

Voyageur Pharmaceuticals says white paper highlights SmoothX's potential as oral contrast agent

By Proactive Investors
June 12, 2023

Voyageur Pharmaceuticals says white paper highlights SmoothX's potential as oral contrast agent

Voyageur Pharmaceuticals has highlighted a new white paper that outlines the imaging properties of its product SmoothX and its potential to optimize a more_horizontal

Voyageur Pharmaceuticals completes field work at Frances Creek project in British Columbia

By Proactive Investors
May 31, 2023

Voyageur Pharmaceuticals completes field work at Frances Creek project in British Columbia

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced that it has successfully completed the environmental and geotechnical field work at its F more_horizontal

Voyageur Pharmaceuticals unveils pioneering agreement with Rain Cage Carbon

By Proactive Investors
May 24, 2023

Voyageur Pharmaceuticals unveils pioneering agreement with Rain Cage Carbon

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) has announced a new development and license agreement with Rain Cage Carbon Inc to develop cuttin more_horizontal

Voyageur Pharmaceuticals aims to be the first vertically-integrated North American supplier of medical imaging contrast agents

By Proactive Investors
April 13, 2023

Voyageur Pharmaceuticals aims to be the first vertically-integrated North American supplier of medical imaging contrast agents

Amid supply chain challenges, demand for medical imaging contrasts such as barium sulfate and iodine which are used by radiologists to diagnose patien more_horizontal

Voyageur Pharmaceuticals reports positive comparative study of SmoothX barium contrast media for CT imaging

By Proactive Investors
April 4, 2023

Voyageur Pharmaceuticals reports positive comparative study of SmoothX barium contrast media for CT imaging

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) said it has completed comparative studies of its SmoothX barium contrast media versus ReadiCat 2% more_horizontal


Search within

Pages Search Results: